

## **EXHIBIT 1**



**UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY )  
AVERAGE WHOLESALE PRICE )  
LITIGATION )

) MDL No. 1456

THIS DOCUMENT RELATES TO )  
01-CV-12257-PBS AND 01-CV-339 )

) CIVIL ACTION: 01-CV-12257-PBS

Judge Patti B. Saris

**PLAINTIFFS' OMNIBUS REQUESTS FOR PRODUCTION AND INTERROGATORIES  
TO DEFENDANTS ABBOTT, AMGEN, AVENTIS, BAXTER, BAYER, BOEHRINGER,  
BRAUN, DEY, FUJISAWA, NOVARTIS, PFIZER, PHARMACIA, SICOR, TAP AND  
WATSON AND TO ALL OTHER DEFENDANTS WITH RESPECT TO DRUGS  
THAT WERE NOT PREVIOUSLY SUBJECT TO DISCOVERY**

Pursuant to Rules 26 and 34 of the Federal Rules of Civil Procedure and LR D. Mass. 26.5 and 34.1, and pursuant to case management orders of this Court including the March 25, 2004 Order, the plaintiffs hereby request that each defendant produce the documents requested herein in compliance with the March 25, 2004 Order.

Prior to the Court's March 25, 2004 Order, several defendants commenced production for specific drugs pursuant to prior document requests. This Omnibus Request does not seek production of documents to the extent that such documents were both previously requested and actually produced by a defendant.

**I. DEFINITIONS**

1. "Agreement" means a contract, arrangement or understanding, formal or informal, oral or written, between two or more persons.
2. "All documents" means every document and every non-identical copy known to you and every such document or writing which you can locate or discover by reasonably diligent efforts, including, but not limited to, documents now in the possession, custody or control of a defendant, its merged or acquired predecessors, its former and present directors, officers, counsel, agents, employees and/or persons acting on its behalf.
3. "AMCC" means the Amended Master Consolidated Complaint.
4. "AMP" or "Average Manufacturer Price" shall have the meaning set forth in 42 U.S.C. § 1396r-8(k)(1).
5. "Any" means one or more.
6. "ASP" means average sales price.



7. "AWP" means the average wholesale price reported to and/or reported by an industry trade publication.

8. "AWPID" means any of the drugs identified in Appendix A to the AMCC and, pursuant to Case Management Order No. 10 dated March 25, 2004, includes all NDC's for that drug, including NDC's not in the AMCC.

9. "Best Price" shall have the meaning ascribed to that term pursuant to 42 U.S.C. § 1396r-8(c)(1)(C).

10. "CMS" means the Centers for Medicare and Medicaid Services.

11. "Communication" means the transmittal of information (in the form of facts, ideas, inquiries, or otherwise).

12. "Concerning" means referring to, describing, evidencing, or constituting.

13. "Covered Drugs" means pharmaceuticals that are reimbursed under Title XVIII of the Social Security Act, 42 U.S.C. § 1395 *et seq.*

14. "Defendant" refers to any of the defendants in the AMCC, its officers, directors, employees, partners, corporate parent, subsidiaries, or affiliates. This definition is not intended to impose a discovery obligation on any person who is not a party to the litigation.

15. "Document" is defined to be synonymous in meaning and equal in scope to the usage of this term in Fed.R.Civ.P. 34(a). A draft or non-identical copy is a separate document within the meaning of this term. The term is used in the broadest possible sense and means without limitation, any written, printed, typed, photostated, photographed, recorded or otherwise reproduced or stored communication or representation, whether comprised of letters, words, numbers, data, pictures, sounds or symbols, or any combination thereof. This definition includes copies or duplicates of documents contemporaneously or subsequently created which have any non-conforming notes or other markings. Without limiting the generality of the foregoing, "document" includes, but is not limited to, correspondence, memoranda, notes, records, letters, envelopes, telegrams, messages, studies, analyses, contracts, agreements, working papers, accounts, analytical records, reports and/or summaries of investigations, trade letters, press releases, comparisons, books, calendars, diaries, articles, magazines, newspapers, booklets, brochures, pamphlets, circulars, bulletins, notices, drawings, diagrams, instructions, notes of minutes of meetings or of other communications of any type, including inter-office and intra-office communications, electronic mail/messages and/or "e-mail," electronically stored telephone messages and/or "voice-mail," questionnaires, surveys, charts, graphs, photographs, phonograph recordings, films, tapes, disks, data cells, print-outs of information stored or maintained by electronic data processing or word processing equipment, all other data compilations from which information can be obtained (by translation, if necessary, by you through detection devices into usable form), including, without limitation, electromagnetically sensitive storage media such as floppy disks, hard disks and magnetic tapes and any preliminary versions, as well as drafts or revisions of any of the foregoing, whether produced or authored by you or anyone else.



16. "EAC" or "Estimated Acquisition Cost" shall have the meaning ascribed to that term pursuant to 42 C.F.R. § 447.301.

17. "Government Investigation" refers to any ongoing or closed investigation conducted by the Commerce, Energy and/or Ways and Means Committees of the United States Congress, the United States Department of Justice, the United States General Accounting Office, Federal Trade Commission, the Office of the United States Inspector General, the United States Department of Health and Home Services, or any other federal, state or local governmental entity without regard to time period.

18. "Government payor" means any federal or state government entity or program that reimburses Providers for drugs or health care services, including but not limited to CMS, Medicare, and Medicaid.

19. "Identify": When referring to a person, "to identify" means to give, to the extent known, the person's full name, present or last known address, and, when referring to a natural person, the present or last known place of employment. Once a person has been identified in accordance with this subparagraph, only the name of that person need be listed in response to subsequent discovery requesting the identification of that person.

20. "Identify": When referring to documents, "to identify" means to give, to the extent known, the

- (a) type of document;
- (b) general subject matter;
- (c) date of the document; and
- (d) author(s), addressee(s), and recipients(s).

21. "Independent Practice Association" means any organized group of providers whose members provide health care to any participant, beneficiary or patient.

22. "MAC" means the maximum allowable cost, and includes the meaning ascribed to that term pursuant to 42 C.F.R. § 442.332.

23. "Manufacturer" means a company that manufactures pharmaceutical products, including, without limitation, AWPIIDs.

24. "Medicare," "Medicare Program" or "Medicare Part B" means the government reimbursement system for prescription pharmaceuticals under Title XVIII of the Social Security Act, 42 U.S.C. § 1395, *et seq.*



25. "Meeting" means any discussion between two or more persons either in person or telephonically.

26. "Participant" and "Beneficiary" means a person for whom a health plan or health and welfare fund provides any medical or health insurance benefit.

27. "PBM" means a pharmacy benefit manager.

28. "Person" means any natural person or any business, legal, or governmental entity or association.

29. "Price" means any measure for the charging, payment or reimbursement of a drug, including but not limited to actual wholesale price, AMP, ASP, AWP, Best Price, direct price, estimated acquisition cost, list price, net wholesale price or other measure, comparison, estimate, benchmark or computation of price, and includes prices both with or without discounts, rebates or other incentives affecting the cost of the drug.

30. "Private payor" means any non-government entity or program that reimburses Providers for drugs or health care services, including but not limited to health insurance companies, health maintenance organizations, preferred provider organizations, self insurance plans, health plans, unions, and welfare and benefit funds.

31. "Provider" means any physician or entity that provides health care to any Participant or Beneficiary.

32. "Publisher" means an entity that publishes a listing of pharmaceutical prices, and includes publications identified in Health Care Financing Administration Program Memorandum AB-99-63 and includes *First DataBank*, *Red Book*, *Blue Book* and *Medispan*.

33. "Relating" means concerning or referring to, consisting of, involving, regarding or connected with the subject matter of the request.

34. "State the Basis." When an interrogatory calls upon a party to "state the basis" of or for a particular claim, assertion, allegation, or contention, the party shall:

(a) identify each and every document, (and, where pertinent, the section, article, or subparagraph thereof), which forms any part of the source of the party's information regarding the alleged facts or legal conclusions referred to by the interrogatory;

(b) identify each and every communication which forms any part of the source of the party's information regarding the alleged facts or legal conclusions referred to by the interrogatory;

(c) state separately the acts or omissions to act on the part of any person (identifying the acts or omissions to act by stating their nature, time and place and identifying the persons involved) which form any part of the party's information regarding the alleged facts or legal



conclusions referred to in the interrogatory; and

(d) state separately any other fact which forms the basis of the party's information regarding the alleged facts or conclusions referred to in the interrogatory.

35. "Third Party Administrator" means any entity that provides administrative services to any health plan or health and welfare fund relating to any medical benefit provided to any participant or beneficiary.

36. "WAC" means wholesale acquisition cost or the list prices for sales by manufacturers to wholesalers.

37. "Wholesaler" means any entity that purchase AWPIDs from a manufacturer and resells such drugs to any other entity.

38. "You" or "Your" means the Defendant responding to these requests.

## II. RULES OF CONSTRUCTION

1. All/Each – The terms "all" and "each" shall be construed as meaning either all and each as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside its scope.

2. And/Or – The connectives "and" and "or" shall be construed either disjunctively and conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside its scope.

3. The use of the singular form of any word shall include the plural and vice versa.

4. The masculine gender includes the feminine.

## III. INSTRUCTIONS

1. Control. A document shall be deemed to be in your control if you have the right to secure the document or copy thereof from another person or public or private entity having possession or custody thereof. If any otherwise responsive document was, but is no longer, in existence or in your possession, custody or control, or has been lost, discarded or destroyed, said document shall be identified as completely as possible including, but not limited to, the following information:

- (a) the date of disposal or disposition from your possession, custody or control;
- (b) the manner of disposal or disposition from your possession, custody or control;
- (c) the reason for disposal or disposition from your possession, custody or control;



- (d) the person authorizing disposal or disposition from your possession, custody or control;
- (e) the document's current or last known custodian;
- (f) the circumstances surrounding the document's disposition from your possession, custody or control;
- (g) the generic category of the document, e.g., memo, letter, computer print-out, etc.;
- (h) the type(s) of information contained in the document; and
- (i) the identity of all persons having knowledge or who had knowledge of the contents of the document.

2. All Documents. Unless otherwise indicated, the documents to be produced include all documents prepared, sent, dated or received, or those which otherwise came into existence at anytime during the relevant period described herein.

3. Objections.

(a) Where an objection is made to any document request under Fed. R. Civ. P. 34, the objection shall state with specificity all grounds. Any ground not stated in an objection within the time provided by the Federal Rules of Civil Procedure, or by the Court's order, or any extensions thereof, shall be waived.

(b) Where a claim of privilege is asserted in objecting to any document demand, or sub-part thereof, and an answer is not provided on the basis of such assertion:

(i) the attorney asserting the privilege shall in the objection to the document demand, or sub-part thereof, identify the nature of the privilege (including work product) that is being claimed and if the privilege is being asserted in connection with a claim or defense governed by state law, indicate the state's privilege rule being invoked; and

(ii) the following information shall be provided in the objection, unless divulgence of such information would cause disclosure of the allegedly privileged information:

(A) for documents: (1) the type of document; (2) general subject matter of the document; (3) the date of the document; and, (4) such other information as is sufficient to identify the document for a subpoena duces tecum, including, where appropriate, the author of the document, the addressee of the document, and, where not apparent, the relationship of the author and addressee to each other;



(B) for oral communications: (1) the name of the person making the communication and the names of persons present while the communication was made and, where not apparent, the relationship of the persons present to the person making the communication; (2) the date and the place of communication; and, (3) the general subject matter of the communication.

4. Non-Objected Sub-Parts. Notwithstanding the assertion of any objection to production, any document to which an objection is raised containing non-objectional subject matter which is relevant and material to a request must be produced, but that portion of the document for which the objection is asserted may be withheld or redacted provided that the above-requested information is furnished.

5. Continuing Duty. This request is continuing and all documents coming into your possession, custody or control which you would have been required to produce had they been available at an earlier time shall be produced forthwith in accordance with the Federal Rules of Civil Procedure.

6. Entire Document. Each document requested herein is requested to be produced in its entirety and without deletion or excisions, regardless of whether you consider the entire document to be relevant or responsive to these requests. If you have redacted any portion of a document, stamp the word "redacted" on each page of the document which you have redacted. Redactions should be included on the privilege log described in Instruction 3.

7. Each Defendant Separate. The fact that a document is produced by one defendant does not relieve any other defendant of the obligation to produce his or its copy of the same document, even if the two documents are identical in all respects.

8. Originals and Non-Identical Copies. In producing documents, you are requested to produce the original of each document requested together with all non-identical copies and drafts of that document. If the original of any document cannot be located, a copy shall be provided in lieu thereof, and shall be legible and bound or stapled in the same manner as the original.

9. Container Intact. All documents shall be produced in the file folder, envelope or other container in which the documents are kept or maintained by you. If, for any reason, the container cannot be produced, produce copies of all labels or other identifying marks.

10. Source Identifiable. Documents shall be produced in such fashion as to identify the department, branch or office in whose possession it was located and, where applicable, the natural person in whose possession it was found and the business address of each document's custodian(s).

11. Don't Separate Attachments. Documents attached to each other should not be separated.



12. Electronic Availability. Any documents available in an electronic format shall be so provided in that format, i.e., in an identical, usable electronic format. If issues regarding compatibility of computer systems and software arise, the producing parties shall confer to resolve the matters. In producing documents consisting of electronically stored data in machine readable form in response to any document request, provide such data in a form that does not require specialized or proprietary hardware or software. Data files typically should be in sequential format, also known as ASCII files or flat files, with the data fields in fixed-column positions. For each data file provided, the following information should be included: a record layout, a short narrative description of the contents of the file, translation of any coded fields, the number of records in the file, and a printout of the first 100 records in report format. A record layout must contain the following pieces of information: name of the field, starting and ending position in the record, length of the field, and characteristics of the field (e.g., packed decimal, zoned decimal, alphanumeric). The magnetic media should be in the most efficient, transferable form. Data typically can be accepted in either ASCII or EBCDIC format. Do not convert the data between ASCII and EBCDIC formats. The record length, blocksize and tape density must be provided. The tapes should be written with generic copy utilities rather than backup programs from a specific operating system. Where multiple magnetic media are necessary, recreation of the entire data must be enabled. For example, where PC files are too large for one diskette, DOS BACKUP disk sets will be acceptable so long as they are accompanied by backup listings. Backup listings may be hard copy or ASCII files on non-backup diskettes. A backup listing must provide the path name necessary to individually restore each file in the backup. Compression utilities are acceptable so long as the utility is provided and such provision does not violate licensing or copyright laws.

13. Don't Alter Contents. No watermarks, stamps of "confidential" or the like shall be on the text or other contents of a document and (if the parties agree to production of photocopies in lieu of originals as requested by this pleading) no reduction of the size of an original document shall be made.

14. Reference Documents. Documents not otherwise responsive to this discovery request shall be produced if such documents mention, discuss, refer to, or explain the documents which are called for by this discovery request, or if such documents are attached to documents called for by this discovery request and constitute routing slips, transmittal memoranda, or letters, comments, evaluations or similar materials.

#### IV. DRUGS AT ISSUE

1. "Class A drugs" means all physician or other provider-administered AWPs and all other AWPs that are, or at any time during the relevant period were, coverable under Medicare Part B.

2. "Class B drugs" are all other AWPs.
3. "All Classes" or "All Drugs" means all drugs identified in the AMCC.



## V. RELEVANT TIME PERIOD

The relevant period of these document requests, unless otherwise indicated, shall be from January 1, 1991, to the date of production and shall include all documents and information which relate in whole or in part to such period, or to events or circumstances during such period, even though dated, prepared, generated or received prior or subsequent to that period.

## VI. REQUESTS FOR PRODUCTION

### Category 1: General Corporate

1. All documents sufficient to identify your policy or practice of document retention, destruction, disposal or preservation during the relevant time period.
2. All current and historical organizational charts for all of your sales, marketing and pricing departments or divisions.
3. Any and all company, organizational and policy information in its entirety, including but not limited to corporate policy and procedure manuals, and policy memoranda.
4. Documents sufficient to identify your electronic mail, document management and other automated information systems.
5. Documents sufficient to identify your electronic mail retention policies.
6. Documents evidencing steps were taken by you (if any) from January 1, 2001 to the present to insure that discoverable information with respect to average wholesale price litigation is not destroyed or otherwise made unavailable.
7. Documents sufficient to identify your policies and procedures concerning the back-up of data for your financial and your marketing, sales and promotion divisions, including but not limited to, the frequency of back-ups, all software and hardware used to perform back-ups, and all media onto which data is backed-up.

### Category 2: Trade Associations

8. All documents received from or provided to any trade association (such as the Pharmaceutical Research and Manufacturers of America), and any of its organizational subcommittees, including meeting agendas and minutes, concerning (i) Medicare reimbursement for drugs and/or the use of AWP in the reimbursement process; (ii) publications identified in Health Care Financing Administration Program Memorandum AB-99-63, including the *Red Book*, *Blue Book*, and *Medispan* ("pharmaceutical industry publications"); or (iii) a Government Investigation or inquiry as to the use of AWP in the reimbursement process.



**Category 3: Governmental Investigations; Litigation**

9. All documents produced by you, whether voluntarily or involuntary, in any governmental investigation or inquiry concerning the use of AWP.
10. All documents relating to any legal proceeding (by country, court, caption, case number, etc.), including but not limited to court hearings, legislative hearings, mediations or arbitrations, in which you were a party or witness, regarding any allegations relating to AWPs.
11. All affidavits, declarations, depositions, or other written statements, including drafts, provided by you regarding any allegations relating to the use of AWP.

**Category 4: Communications With Governmental Entities**

12. All documents created by or received from CMS, the United States Department of Health and Human Services, the Health and Human Services Office of the Inspector General, the General Accounting Office, Congress or any other federal institution, agency, department, or office concerning prices for prescription drugs.
13. All documents provided to CMS, the United States Department of Health and Human Services, and Department of Health and Human Services Office of the Inspector General, the General Accounting Office, Congress, or any other federal institution, agency, department, or office concerning the price of any AWPID.

**Category 5: AWPs and Pricing Related**

14. All documents concerning any definition or meaning of AWP, including documents discussing how you or others define AWP.
15. All documents discussing how the AWP has been or is currently determined for any AWPID.
16. As to each of your AWPDs, all documents concerning any actual, proposed, or prospective AWP announcements, changes or price lists, including the methodology and procedures used by you in considering whether to increase or decrease the AWP of each AWPID.
17. As to each of your AWPDs, all documents concerning any actual, proposed or prospective price announcement, price change or price list, including the methodology and procedures used by you in considering whether to increase or decrease the price for each AWPID.
18. As to Class A drugs only, all sales-level detailing reports where AWPs, reimbursement based on AWPs, or the prices for AWPDs was discussed. (Class A Drugs)
19. As to Class A drugs only, all sales-level detailing reports where price, discounts,



rebates, price concessions, forgiveness of debt, free samples, educational grants or other remuneration were discussed with a purchaser or potential purchaser of any of your AWPIDs.

20. All documents, including organizational charts, that describe or list the individuals responsible for determining the price for each AWPID.

21. All documents, including organizational charts, that describe or list the individuals responsible for determining the price for each AWPID.

22. For each of your AWPIDs, all documents concerning the "product market," as defined in the 1992 Department of Justice and Federal Trade Commission Horizontal Merger Guidelines, in which each AWPID competes including, but not limited to, all documents that: (a) discuss, address, concern, regard, or reflect products that have a significant cross-elasticity of demand, or that are reasonably substitutable for, interchangeable with, or close therapeutic equivalents and/or (b) discuss, address, concern, regard, or reflect whether, and to what extent, the marketing, pricing, and/or sale of a drug other than your AWPID has caused, or could or might cause, physicians, consumers, and other individuals or entities to terminate or reduce their purchase or use of your AWPID.

23. For each of your AWPIDs, all documents concerning the "geographic market" or markets in which the AWPID competes including, but not limited to, all documents that (a) discuss, concern, regard, or reflect the geographic area within which the AWPID is marketed, and (b) discuss, concern, regard or reflect the area within which you and your competitors view themselves as competing with respect to the AWPID.

24. For each of your AWPIDs, all documents concerning your strategic and marketing plans including, but not limited to all pricing, reimbursement, brand switching, and consumer segmentation studies and/or surveys.

25. For each of your AWPIDs, all documents (in digital, computerized form where available) that identify each customer who purchased the AWPID. For each of these purchasers, all documents that reflect:

- (a) Each sale or other transaction involving the AWPID including the date thereof;
- (b) The number or units of the AWPID sold by dosage strength and package size for each sale or other transaction;
- (c) The invoice amount in dollars for each sale or other transaction concerning the AWPID;
- (d) Discounts, rebates, chargebacks, and other price adjustments relating to each sale, transaction, or set of transactions involving or relating to the AWPID;
- (e) The net amount in dollars for each sale or transaction concerning the AWPID;
- (f) Any other price or unit adjustments – whether monthly, quarterly or on any other basis – involving or relating to sales or transaction involving the AWPID;



(g) The full name and address of each entity purchasing the AWPID (and, in addition, the full name and address of the parent company where the database or documents identify a subsidiary, corporate affiliate, division, satellite office, or warehouse).

26. For each of your AWPIDs, all documents that reflect the prices charged to, or terms of conditions of sale for, purchasers of the AWPID including, but not limited, to:

- (a) The wholesale acquisition price or other published price of the AWPID or any generic equivalent;
- (b) Payment terms;
- (c) discounts, rebates, chargebacks or other adjustments offered to any class of purchaser;
- (d) Prices and terms of sales for wholesale purchasers;
- (e) Prices and/or discounts and/or rebates or other adjustments for chain pharmacy purchasers;
- (f) Prices and/or discounts and/or rebates or other adjustments for hospital purchasers;
- (g) Prices and/or discounts and/or rebates or other adjustments for managed care purchasers;
- (h) Prices and/or discounts and/or rebates or other adjustments for pharmacy benefit managers;
- (i) Prices and/or discounts and/or rebates or other adjustments for internet pharmacies;
- (j) Prices and/or discounts and/or rebates or other adjustments for mail order purchasers; and
- (k) Prices and/or discounts and/or rebates or other adjustments for any other purchaser class or subgroup.

27. For each of your AWPIDs, documents sufficient to show, in digital or computerized form, in chronological order:

- (a) The date of each sales transaction;
- (b) Every discount, rebate, and/or any other adjustment that any customer of D has received;



- (c) The date each discount, rebate, and/or any other adjustment was given;
- (d) The time period covered by each discount, rebate, and/or any other adjustment;
- (e) Sales in units by National Drug Code sold, shipped, and/or returned by dosage form, strength, and package size;
- (f) Sales in dollars by National Drug Code sold, shipped, and/or returned by dosage form, strength, and package size;
- (g) Net sales in dollars for each sale;
- (h) The name, address, account number, and all other identifying numbers or codes for the person or entity billed, invoices, and/or credited for the transaction; and
- (i) The name, address, account number, and all other identifying numbers or codes for the person or entity to whom the product was shipped or from whom product returns were received.

28. For each of your AWPIDs, documents sufficient to identify:

- (a) The published AWP;
- (b) AMP;
- (c) ASP;
- (d) EAC;
- (e) WAC;
- (f) MAC;
- (g) Earned margin (difference between AWP and actual product cost);
- (h) Documents that indicate whether the AWP, ASP, AMP and Earned Margin include all rebates, chargebacks, discounts, allowances, credits, administrative fees, price/volume discounts and any other incentives provided to third parties.
  - (i) Documents summarizing all rebates, chargebacks, discounts, allowances, credits, administrative fees, price volume discounts or other incentives.

29. For each of your AWPIDs, all agreements for sale of the AWPID, whether or not those contracts are with customers who purchased the AWPID directly, including drafts, correspondence, and supporting detail and data (in computerized form where available).



30. All documents concerning communications between you and IMS Health (or any similar entity providing pharmaceutical database information) concerning or relating to any of your AWPIDs.

31. For each of your AWPIDs, documents sufficient to estimate the number of patients taking the AWPID over each one year period.

32. For each of your AWPIDs, all documents concerning your actual, potential, or expected revenues and/or profits from the sale of that AWPID.

33. All documents concerning or relating to the actual or potential impact of the pricing or reimbursement of any drug on the quantity of any of your AWPIDs that have been or might be sold.

34. Documents sufficient to show your per-unit average total cost for each of your AWPIDs, and the components that make up that figure, including but not limited to raw materials, manufacturing, marketing, sales and packaging costs.

35. All documents concerning or relating to the difference between an AWP and any other price for any AWPID.

**Category 6: Inducements**

36. All documents describing any discount programs (including but not limited to volume discounts), rebates, incentives, or penalties for each AWPID.

37. All documents relating to the use or provision of free samples, educational grants, marketing grants, and payments for specific data gathering or other incentives relating to any AWPID.

38. All documents evidencing any "credit memos" or credit extended to hospitals, GPOs or other purchasers of AWPIDs, including but not limited to credit memos or credit issued via a wholesaler to a purchaser, and/or credit for the purpose of "returned goods."

39. All documents setting forth the circumstances in which credit against the purchase of AWPIDs was or could be given to any hospital, GPO, HMO, physician, wholesaler or other purchaser of AWPIDs.

40. All documents setting forth the circumstances in which credit against the purchase of AWPIDs was or could be given to any hospital, GPO, HMO, physician, wholesaler or other purchaser of AWPIDs.

41. All documents relating to or reflecting any payments you gave to providers relating to any AWPID. (Class A Only)



42. All documents evidencing any chargebacks with respect to the sale of an AWPID.

**Category 7: Marketing Plans and Sales Representatives**

43. Documents sufficient to determine complete contact information for all personnel with responsibility for marketing and promotional activity for AWPDs. Include Marketing Department Product or Brand Managers, and members of Marketing Advisory Boards, and include home address and telephone number. (Class A Drugs)

44. A list of all national level sales awards available for each AWPID. (Class A Drugs)

45. Quarterly, semi-annual and annual business plans for each winner of the top national sales award winners and direct supervisors. (Class A Drugs)

46. Any summaries or reports made by a sales representative that evidence a discussion between that sales representative and a provider regarding AWPs for AWPDs, reimbursements based on AWPs for AWPDs, and any difference between what the provider is reimbursed for AWPDs and what the provider pays for the AWPID. (Class A Drugs)

47. For each AWPID, sales representatives' field notes for the top 50 sales representatives for each year. (Class A Drugs)

48. Documents sufficient to describe any computer programs that you employ or have employed to manage your sales force, including but not limited to programs that collect data on the number of provider contacts and summarize the nature of the discussions between your sales representatives and providers. Examples of such programs include programs marketed by Siebel Systems and ImpactRx, as well as any programs developed by you. (Class A Drugs)

49. All documents relating to discussions between sales managers and sales representatives after field visits where AWPs, reimbursement rates, or the spread was discussed. (Class A Drugs)

50. All documents evidencing any meetings where raising the AWP, or use of AWP as a marketing tool, on any AWPID was discussed. (Class A Drugs)

51. All communications between you and any party in the reimbursement cycle or pharmacies relating to reimbursement and AWP. (Class A Drugs)

52. All documents relating to any requests by you for any information concerning the reimbursement, pricing or payment for any subject drug. (Class A Drugs)

53. All documents relating to all actual, proposed, or prospective marketing methods, practices, policies, or strategies for each AWPID to the extent such documents refer to AWP, the spread, or to discounts of any type.



54. All documents relating to any communication with doctors, other health care professionals, or any person or entity providing health care services to seek Medicare reimbursement or consumer co-payment for free samples of each AWPID you provided to them. (Class A Drugs)

55. All marketing and sales materials which compare the AWP, price, market share, rebates, pricing discounts, incentives, or penalties for each AWPID with the AWP of any other pharmaceutical. (Class A Drugs)

**Category 8: Publishers**

56. All documents concerning communications between you and any publisher concerning measures of price for pharmaceuticals, including ASP, AWP, WAC or other measures of price.

57. For each of your AWPIDs, separately produce all documents concerning communications between you and a publisher regarding the price(s) for that AWPID.

58. All documents concerning your role in the publication, appearance and/or advertisement of the AWP, WAC or other price measure for your AWPIDs in any publication of a publisher.

59. All documents concerning the role of the publisher in the publication, appearance and/or advertisement of the AWP, WAC or other price measure for each of your AWPIDs in a publication of a publisher.

60. All documents relating to the role of some person other than yourself and the publisher in the publication, appearance and/or advertisement of the AWP, WAC and/or other price measure for each of your AWPIDs in any publication of a publisher.

61. All documents relating to your role in the publication, appearance, or advertisement of the AWP, WAC or other pricing information in any pharmaceutical-related industry publications, including publications of the publishers.

62. All documents concerning the use by any participant in the drug distribution/sales channels (e.g., wholesalers, retailers, pharmacies, pharmacy benefit managers, insurers, etc.).

63. All documents concerning agreements between you and any publisher.

64. All documents concerning any payments made by you to a publisher, where such payments related in any way to drug pricing.

65. All documents relating to any investments or loans that you have made in or to a publisher.

66. All notes or minutes of any meetings between you and a publisher where drug



pricing was discussed.

67. All documents concerning communications between you and a publisher about litigation involving AWP or drug pricing.

68. All documents regarding any pricing surveys that publishers have done for AWPsIDs. (All Drugs).

69. All documents regarding communications between you and a publisher about drug reimbursement systems, including Medicare, Medicaid and private insurance. (All Drugs)

**Category 9: PBMs; Wholesalers**

70. All documents concerning your contractual relationships with wholesalers, independent practice associations, pharmacies or providers insofar as they cover AWPsIDs, including, without limitation, master agreements, addenda, schedules, attachments, requests for proposal, responses to requests for proposal and correspondence.

71. Documents sufficient to identify all persons involved in negotiation of contractual relationships with wholesalers, manufacturers, independent practice associations, pharmacies, PBMs or providers insofar as they cover any AWPsID.

72. All documents relating or referring to your contractual relationships with PBMs insofar as they cover AWPsIDs, including, without limitation, master agreements, addenda, schedules, attachments, requests for proposal, responses to requests for proposal and correspondence.

73. Documents sufficient to identify all persons involved in negotiation of contractual relationships with PBMs insofar as they cover any AWPsID.

74. All documents relating to marketing materials that you have provided PBMs for any AWPsID.

75. All documents relating to any communications between you and PBM regarding AWP, or to any fees or monies paid to or retained by a PBM.

76. All documents relating to any communications between you and any PBM regarding the revenue, profit, spread or other consideration that a PBM would earn based on any difference between your price for any AWPsID and the compensation that the PBM receives for the AWPsID.

77. All documents relating to the pricing of any of your AWPsIDs sold to or through any PBM.

78. All documents relating to any rebates that you have provided PBMs for any AWPsID.



79. Excluding Rebates, all documents referring or relating to your provision of any other consideration to a PBM for AWPIDs, including but not limited to:

- a. Administrative fees for assembling data to verify market share results;
- b. Fees for selling other data;
- c. Fees for encouraging physicians to change prescribing patterns;
- d. Prompt payment discounts;
- e. Free drugs;
- f. Drug samples;
- g. Credit memos or credit extended to any PBM, including but not limited to credit memos or credit issued for the purported reason of "returned goods;"
- h. Other discounts, fees or grants.

80. All documents relating to the placement of any of your AWPIDs on a PBM formulary.

**Category 10: Communications With Other Manufacturers**

81. All documents relating to any communications, including meetings, between you and any other pharmaceutical company regarding:

- (a) any actual, proposed or prospective price, price announcements, price changes, or price lists for any AWPID;
- (b) any actual, proposed, or prospective pricing methods, practices, policies or strategies for any AWPID;
- (c) any actual, proposed, or prospective marketing methods, practices, policies, or strategies for any AWPID;



(d) any actual, proposed, or prospective pricing discounts, rebates, bids, or incentives for any AWPID;

- (e) territories or markets for sales or potential sales for any AWPID;
- (f) Medicare Part B and its policy of reimbursement for any AWPID;
- (g) the AWP of any AWPID;
- (h) pharmaceutical industry publications; and
- (i) market conditions or market shares.

**Category 11: Miscellaneous**

82. Any documents relating to the repackaging or relabeling of any AWPID including but not limited to: (a) documents indicating that any AWPID with a specific NDC has been repackaged and is being sold with a different NDC, but is the same drug; and (b) for any repackaged AWPID, documents evidencing the AWP of the original AWPID and of the repackaged AWPID, and documents evidencing the bases, methods and/or reasons for any change in the AWP.

## VII. INTERROGATORIES

1. For the period beginning January 1, 1997, and for each subsequent calendar quarter, and with respect to each of the AWPs, identify the following information:

- a. the total volume of sales, indicating both the number of units and net revenue;
- b. the "average wholesale price" (AWP), as reported in Medical Economics *Red Book*, *First Data Bank* and/or *MediSpan*, and the volume of sales (in both units and net revenue) occurring (i) at or within five percent of AWP, whether higher or lower, (ii) at more than five percent above AWP, and (iii) at more than five percent below AWP;
- c. the "average manufacturer price" ("AMP"), as reported to the Secretary of Health and Human Services, pursuant to the requirements of Social Security Act ("SSA") § 1927(b)(3), and the volume of sales (in both units and net revenue) occurring (i) at AMP and up to and including 10% above AMP, and less than or equal to 10% below AMP (broken out separately), (ii) at greater than 10% above AMP but less than or equal to 20% above AMP, and at greater than 10% below AMP but less than or equal to 20% below AMP (broken out separately), (iii) at greater than 20% above AMP but less than or equal to 30% above AMP, and at greater than 20% below AMP but less than or equal to 30% below AMP (broken out separately), (iv) at greater than 30% above AMP but less than or equal to 40% above AMP, and at greater than 30% below AMP but less than or equal to 40% below AMP (broken out separately), and (v) at greater than 40% above AMP but less than or equal to 50% above AMP,



and at greater than 40% below AMP but less than or equal to 50% below AMP (broken out separately);

d. the "wholesale acquisition cost" ("WAC"), as reported by Medical Economics *Red Book*, *First Data Bank* and/or *MediSpan* or any other such entity that gathers and publishes "wholesale acquisition costs," and the volume of sales (in both units and net revenue) occurring (i) at or within five percent of WAC, whether higher or lower, (ii) at more than five percent above WAC, and (iii) at more than five percent below WAC;

e. the "average sales price" (ASP), i.e., the price after reflecting discounts, rebates, chargebacks, to all classes except FSS;

f. the total volume of the subject drug, in units, distributed as free goods.

2. For the period beginning January 1, 1997, to the present, has the distribution, marketing, sales or promotion of any AWPID considered, incorporated, or been based upon, in any way, the difference between the cost to the provider and the amount that the provider receives for reimbursement or sale? If so, please describe the circumstances of such distribution, marketing, sales, or promotion, and provide all documents relating thereto, and identify all past and current employees with knowledge of the facts relating to such marketing, sales or promotion.

3. For the period of January 1, 1997, to the present, please state for each calendar quarter the largest single purchaser, in terms of units, of each of the AWPIDs and the following:

- a. the total number of units of the AWPIDs received by that purchaser; and
- b. the total net revenue received for the AWPIDs by your company from that purchaser.

Please also produce the contract or agreement governing your relationship with that purchaser for each relevant quarter.

4. For the period of January 1, 1997, to the present, and for each subject drug, please provide a list of all purchasers who received the subject drug at a price exempted from the calculation of the Medicaid "best price," pursuant to the requirements of SSA 1927(c)(1)(C)(ii)(III), and, for each such purchaser, indicate the volume of the AWPID received by calendar quarter, in units, and the range of prices at which such purchaser received the subject drug for that quarter.


5. With respect to each AWPID, please describe how you calculate the prices and/or data reported to Medical Economics *Red Book*, *First Data Bank* or *MediSpan* or any other such entity that gathers and publishes either "average wholesale prices," "list prices," or "wholesale acquisition costs." And for each drug identify the persons responsible for doing so. (All Drugs)



6. Identify the source of each of the documents produced in response to plaintiffs' requests for the production of documents throughout this litigation by identifying the person(s) who possessed those documents, the job position of any such individuals, and the division and department where such documents were located. If you are unable to determine the individual(s) who possessed the documents, identify the department and division where they were/are located when produced.

DATED: March 31, 2004

By

  
Thomas M. Sobol (BBO # 471770)  
Edward Notargiacomo (BBO #567636)  
Hagens Berman LLP  
225 Franklin Street, 26<sup>th</sup> Floor  
Boston, MA 02110  
Telephone: (617) 482-3700  
Facsimile: (617) 482-3003

**LIAISON COUNSEL**

Steve W. Berman  
Sean R. Matt  
Hagens Berman LLP  
1301 Fifth Avenue, Suite 2900  
Seattle, WA 98101  
Telephone: (206) 623-7292  
Facsimile: (206) 623-0594

Samuel Heins  
Brian Williams  
Heins Mills & Olson, P.L.C.  
3550 IDS Center  
80 South Eighth Street  
Minneapolis, MN 55402  
Telephone: (612) 338-4605  
Facsimile: (612) 338-4692

Jeff Kodroff  
John Macoretta  
Spector, Roseman & Kodroff, P.C.  
1818 Market Street, Suite 2500  
Philadelphia, PA 19103  
Telephone: (215) 496-0300  
Facsimile: (215) 496-6611

**CHAIRS OF LEAD COUNSEL  
COMMITTEE**



Marc H. Edelson  
Alan Hoffman  
Hoffman & Edelson  
45 West Court Street  
Doylestown, PA 18901  
Telephone: (215) 230-8043  
Facsimile: (215) 230-8735

Kenneth A. Wexler  
Elizabeth Fegan Hartweg  
The Wexler Firm  
One North LaSalle Street, Suite 2000  
Chicago, IL 60602  
Telephone: (312) 346-2222  
Facsimile: (312) 346-0022

**MEMBERS OF LEAD COUNSEL  
COMMITTEE AND EXECUTIVE  
COMMITTEE**

Michael McShane  
Alexander, Hawes & Audet, LLP  
300 Montgomery Street, Suite 400  
San Francisco, CA 94104  
Telephone: (415) 982-1886  
Facsimile: (415) 576-1776

Robert E. Piper, Jr.  
Piper & Associates  
624 Pierre Avenue  
Shreveport, LA 71103  
Telephone: (318) 226-0826  
Facsimile: (318) 424-9900

**MEMBERS OF EXECUTIVE  
COMMITTEE**

Anthony Bolognese  
Bolognese & Associates  
One Penn Center  
1617 JFK Boulevard, Suite 650  
Philadelphia, PA 19103  
Tel: (215) 814-6750  
Fax: (215) 814-6764

Jonathan W. Cuneo  
The Cuneo Law Group  
317 Massachusetts Avenue, N.E.  
Suite 300  
Washington, D.C. 20002  
Tel: (202) 789-3960  
Fax: (202) 789-1813



Neal Goldstein (Of Counsel)  
Freedman & Lorry, PC  
400 Market Street, Suit 900  
Philadelphia, PA 19106  
Tel: (215) 925-8400  
Fax: (215) 925-7516

Michael E. Criden  
Hanzman & Criden, PA  
Commerce Bank Center, Suite 400  
220 Alhambra Circle  
Coral Gables, FL 33134  
Tel: (305) 357-9000  
Fax: (305) 357-9050

Blake M. Harper  
Kirk B. Hulett  
Hulett Harper LLP  
550 West C Street, Suite 1700  
San Diego, CA 92101  
Tel: (619) 338-1133  
Fax: (619) 338-1139

Jonathan D. Karmel  
Karmel & Gilden  
221 N. LaSalle Street  
Suite 1414  
Chicago, IL 60601  
Tel: (312) 641-2910  
Fax: (312) 641-0781

Dianne M. Nast  
Roda & Nast, PC  
801 Estelle Drive  
Lancaster, PA 17601  
Tel: 717-892-3000  
Fax: 717-892-1200

Henry H. Rossbacher  
Rossbacher & Associates  
811 Wilshire Boulevard,  
Suite 1650  
Los Angeles, CA 90017-2666  
Tel: (213) 895-6500  
Fax: (213) 895-6161

Jonathan Shub  
Sheller, Ludwig & Badley, P.C.  
1528 Walnut Street, 3rd fl  
Philadelphia, PA 19102  
Tel: (215) 790-7300  
Fax: (215) 546-0942



Scott R. Shepherd  
Shepherd & Finkleman, LLC  
117 Gayley Street, Suite 200  
Media, PA 19063  
Tel: (610) 891-9880  
Fax: (610) 891-9883

Lisa J. Rodriguez  
Ira Neil Richards  
Trujillo Rodriguez & Richards, LLC  
The Penthouse  
226 West Rittenhouse Square  
Philadelphia, PA 19103  
Tel: (215) 731-9004  
Fax: (215) 731-9044


Mitchell A. Toups  
Weller, Green, Toups & Terrell, L.L.P.  
2615 Calder Street, Suite 400  
P.O. Box 350  
Beaumont, TX 77704  
Tel: (409) 838-0101  
Fax: 409-838-6780

Damon Young  
Lance Lee  
Young, Pickett & Lee  
4122 Texas Boulevard  
P.O. Box 1897  
Texarkana, AR/TX 75504  
Tel: (903) 794-1303  
Fax: 903-792-5098; 903-794-5098

**ADDITIONAL ATTORNEYS FOR  
PLAINTIFFS**

**CERTIFICATE OF SERVICE**

I hereby certify that I, Thomas M. Sobol, an attorney, caused a true and correct copy of the foregoing Plaintiffs' Omnibus Requests For Production And Interrogatories To Defendants Abbott, Amgen, Aventis, Baxter, Bayer, Boehringer, Braun, Dey, Fujisawa, Novartis, Pfizer, Pharmacia, Sicor, Tap And Watson And To All Other Defendants With Respect To Drugs That Were Not Previously Subject To Discovery to be served on all counsel of record electronically on March 31, 2004, pursuant to Section B of Case Management Order No. 2.

  
Thomas M. Sobol, Esq.  
**HAGENS BERMAN LLP**  
225 Franklin Street, 26<sup>th</sup> Floor  
Boston, MA 02110  
Telephone: (617) 482-3700

## **EXHIBIT 2**

**Sean Matt**

---

**From:** Sean Matt  
**Sent:** Tuesday, April 27, 2004 2:32 PM  
**To:** Merle DeLancey (E-mail)  
**Subject:** Letter Re: Baxter

April 27, 2004

**Via Electronic Mail**

Merle M. DeLancey, Jr.  
DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP  
2101 L Street NW  
Washington, DC 20037-1526

Re: AWP Discovery/Baxter Meet and Confer

Dear Mr. DeLancey:

We write in reference to our telephone conference yesterday regarding the outstanding discovery served by plaintiffs on Baxter. Below are the items that I promised to follow-up on.

1. Purported "de minimus" drugs. You advised that several of the Baxter drugs targeted in the AMCC are predominantly consumed in an in-patient hospital setting where reimbursements are not made based on AWP and therefore have very low sales volumes in the outpatient setting (the purported "de minimus drugs"). In light of this, you questioned whether plaintiffs would initially accept the production of limited data on these drugs in lieu of a broader production for such drugs. Plaintiffs agree to review a limited data production for the drugs that Baxter contends are *de minimus* drugs provided that the following conditions are met. First, for each drug that Baxter contends are *de minimus*, Baxter provides the following information: (i) total annual sales, broken out by each distribution channel; and (ii) all WACs and ASPs.<sup>111</sup> Second, Baxter produces the data on or before June 15, 2004. Third, the limited data production is without prejudice to plaintiffs' ability to later pursue the relevant documents for these drugs. If Baxter agrees to these points, plaintiffs will agree that Baxter does not immediately have to gather documents for these drugs until we review the limited financial data that Baxter will produce.

2. Sampling of Contracts, etc. Request for Production Nos. 70-72 seek the production of contracts with wholesalers, pharmacies, providers, and PBMs *et al.* You have asked whether plaintiffs will agree that Baxter need only produce a sampling of its contracts with others down the distribution chain – say the “Top 10” in each category. Plaintiffs cannot agree. The requests were crafted to obtain a broad perspective on Baxter’s relationships with all of these players, and limiting responses to only a small subset will impede this endeavor.



# Sterne Technical

370 Crescent Street Waltham, MA 02453-3804  
617.438.9585  
[www.truetechsupport.com](http://www.truetechsupport.com)

## **Invoice**

Date	Invoice #
6/15/2006	324

**Bill To**

---

Hagens Berman Sobol Shapiro  
1301 5th Ave #2900  
Seattle, WA 98101


**Job Location**

---

Hagens Berman Sobol Shapiro  
1 Main Street  
Cambridge, MA 02142

		P.O. Number	Terms	Rep	Project
		Due on receipt		CGC	
Quantity	Item Code	Description		Price Each	Amount
1	Monthly Service 10hour	Monthly Service Contract (Verbal) 10 Hours: Pre-payment for month of July 2006(overages will be invoiced separately at end of billing cycle)		1,000.00	1,000.00
			Sales Tax (5.0%)	\$0.00	
			Total	\$1,000.00	
			Payments/Credits	\$0.00	
			Balance Due	\$1,000.00	

## **EXHIBIT 3**



SEAN R. MATT  
(206) 224-9327  
[sean@hagens-berman.com](mailto:sean@hagens-berman.com)

May 26, 2004

Via Facsimile

Merle M. DeLancey, Jr.  
DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP  
2101 L Street NW  
Washington, DC 20037-1526

Re: AWP Discovery/Baxter Meet and Confer

Dear Merle:

We write in response to your letter of May 10, 2004 and your e-mail of May 12, 2004, as part of our continuing dialogue regarding Baxter's responses to plaintiffs' discovery requests. For ease of reference, our responses below mirror the categories contained in your correspondence.

**Items Identified in Your May 10 Letter:**

1. Purported “*de minimis*” drugs. For the data sample on purported “*de minimis*” drugs consumed predominantly in an in-patient setting where reimbursements are not made based on AWP, your proposal to limit the data to the years 1997 through 1999 is acceptable with two exceptions (and subject to plaintiffs’ reservation to later pursue additional data and other relevant documents for these drugs). First, you advise that for certain drugs not sold by Baxter during the 1997 to 1999 time period, Baxter cannot provide the requested information. If this data cannot be produced for that particular time period, then we would like to see data from another time period. It would seem that Baxter can provide this information, and it should. Second, for the drugs that Baxter contends are “*de minimis*,” Baxter will have at its fingertips ASP data that it reported to CMS on April 30 for any “*de minimis*” drugs that are also covered by Medicare Part B. Accordingly, plaintiffs request that Baxter provide its submission to CMS for all *de minimis* drugs at issue in the AMCC, including Addendum A of the submission showing NDC, ASP and number of units for each drug.<sup>1</sup>

---

<sup>1</sup> Indeed, this information should be produced for all of the drugs at issue in the AMCC that are covered by Medicare Part B and not just purported *de minimis* drugs.

Merle M. DeLancey, Jr.  
May 26, 2004  
Page 2

2. Sampling of Contracts. Plaintiffs previously rejected Baxter's suggestion that it produce a sample of contracts with its top 10 customers, explaining that this proposed limitation will not provide a broad perspective on Baxter's relationships with all of the relevant players. In response, you assert that this position is somehow inconsistent with the AMCC's allegation that Baxter has engaged in an organization-wide and deliberate scheme to inflate AWPs for all or almost all of its drugs. We see nothing inconsistent between the allegations and the position and believe that the allegation supports the quest for a broader perspective on relationships than Baxter is willing to provide. Indeed, the allegations suggest that we should not agree to a sampling but receive all contracts.

You further advise that producing all documents concerning Baxter's contractual relationships with wholesalers, pharmacies, providers and PBMs – the information sought in Request for Production Nos. 70-72 – will be an unduly burdensome endeavor resulting in the production of thousands of boxes of documents involving approximately 67,000 customer relationships. Consequently, you propose that Baxter produce documents concerning its contractual relationships with its top three customers (in terms of aggregate annual sales dollars) in each of the following customer categories: wholesalers, distributors, hospital/GPOs, homecare, and physician practices. You predict that such a production would provide information on 15 customers (three per year) or more given that top customers can change annually.

At this point, plaintiffs will agree to accept a sampling production without prejudice to seeking additional documents at a later date regarding Baxter's contractual relationships. The categories that you propose are acceptable with the addition of PBMs, as is the time period (five years). However, plaintiffs still seek a sample broader than just the "top three" by aggregate annual sales dollars. Our proposal: for each category, provide the "top 25," "middle 25," and "bottom 25." For the PBMs, contracts with AdvancePCS, Caremark, Express Scripts, Medco and their predecessor entities would suffice. For wholesalers, contracts with McKesson, AmerisourceBergen and Cardinal will suffice. This should be only a modest expansion of the documents that must be retrieved and produced and will provide a broader cross section of evidence. Also, plaintiffs request that Baxter consider creating an index of contracts. With a potential universe as broad as 67,000, such an index could prove to be a very useful tool in making additional, focused requests for contracts that minimizes the burden on Baxter.

3. Relevant Time Period. This is an area in which we simply must agree to disagree. In any event, the pending motion on this issue will resolve the disagreement. In the interim, Baxter should produce responsive documents from Baxter employee files that have not been archived, as you propose, and we can go from there.

Merle M. DeLancey, Jr.  
May 26, 2004  
Page 3

4. 30(b)(6) Deponents. You continue to express some skepticism regarding the usefulness of producing witnesses in mid-June while Baxter is still in the process of locating and identifying responsive documents. Upon reconsideration, we agree that it makes sense to wait a little longer before holding these depositions. We would aim to conduct the depositions in late July or August and can discuss this more as the Baxter production begins.

5. Written Responses and Objections. We are in agreement that June 1, 2004 is the date.

6. Timing of Production. Plaintiffs have pressed to have Baxter complete its production by August 1, 2004, yet you advise that Baxter will not be able to provide an estimated date by which its production will be completed until the parties have concluded their negotiations on the scope of production. Given the compromises that appear to be reached in this letter, it would appear that Baxter should have a better idea. In any event, given that the requests have been outstanding for almost 60 days, plaintiffs believe that Baxter should be able to complete the initial "compromise" production by September 1, a total response time of five months and one month longer than our prior position (and three months longer than the time provided for in CMO No. 10).

**Items Identified in Your May 12 Email:**

7. Corporate Policies and Procedures. Request No. 3 seeks "[a]ny and all company, organizational and policy information in its entirety, including but not limited to corporate policy and procedure manuals, and policy memoranda." You advise that the request would call for the production of tens of thousands of documents and therefore request that plaintiffs identify the specific topic areas for which corporate policies and procedures are sought. Here are the specific topic areas:

- Document retention
- The setting of drug prices, discounts, rebates, and any other constituents of drug prices
- Reporting of AWPs and other pricing metrics to persons and entities outside of Baxter
- Relationships with PBMs, wholesalers, distributors, hospitals/GPOs, homecare and physician practices
- The tracking of financial data related to drug sales
- Marketing plans and sales force presentations
- Sales force compensation

Merle M. DeLancey, Jr.  
May 26, 2004  
Page 4

- Interactions with trade associations
- Interactions with governmental entities with regard to drug reimbursement

8. Automated Information Systems. Request No. 4 seeks “[d]ocuments sufficient to identify your electronic mail, document management and other automated information systems.” You have asked that plaintiffs more particularly define “other automated information systems.” The additional systems referenced are:

- For each Baxter drug at issue in the AMCC, systems that maintain historical and current sales and profit data for drug sales, including but not limited to drug pricing, discounts, rebates, other financial inducements that Baxter offers; gross sales; net sales; gross margin; and net margin
- Systems maintained with regard to reporting drug pricing information to persons and entities outside of Baxter
- Systems utilized by marketing personnel to craft and save marketing presentations
- Systems utilized by the sales force in selling drugs, including but not limited to automated individual sales representative “call notes” and any other automated system that captures information related to the sales calls made by sales representatives

9. Back-Up Data. Request No. 7 seeks “[d]ocuments sufficient to identify your policies and procedures concerning the back-up of data for your financial and your marketing, sales and promotion divisions, including but not limited to, the frequency of back-ups, all software and hardware used to perform back-ups, and all media onto which data is backed-up.” You have asked that plaintiffs “more specifically state what plaintiffs are seeking or not seeking” in this request. To clarify, this request seeks information related to Baxter’s retention of historical information for each of the categories enumerated in Request No. 7. Examples include documents evidencing how long and in what format the information is maintained and documents sufficient to identify the persons and departments responsible for maintaining the data. This request does not seek the production of documents related to Baxter’s disaster recovery programs.

10. Transaction Data. Let’s have a brief discussion among counsel regarding data fields and formats for transaction data; I am in the office for the remainder of the week. We can then determine whether it is necessary to bring in the IT folks and can, if the need arises, quickly inject the experts into the conversation.

Merle M. DeLancey, Jr.  
May 26, 2004  
Page 5

Please call if you have any questions.

Sincerely,



Sean R. Matt

cc: Steve W. Berman, Esq.